<DOC>
	<DOCNO>NCT00249782</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness ACZONE™ gel compare placebo ( inactive substance ) , MetroGel® combination ACZONE™ gel MetroGel® treatment rosacea . ACZONE™ gel , 5 % topical ( applied skin ) medication approve United States Food Drug Administration ( FDA ) treatment acne vulgaris people 12 year old . The use ACZONE™ treatment rosacea investigational . An investigational use one approve FDA . Subjects apply study treatment 12 week . Efficacy assessment perform baseline Weeks 2 , 4 , 8 , 12 . Laboratory assessment conduct baseline Week , 2 , 4 12 .</brief_summary>
	<brief_title>A Phase II , Randomized Study ACZONE™ ( Dapsone ) Gel , 5 % Papulopustular Rosacea .</brief_title>
	<detailed_description>Study Objective : •To evaluate safety preliminary efficacy ACZONE subject papulopustular rosacea Study Population : Approximately 400 male female subject enrol 27 study center United States . Study Treatment : Subjects randomize 1 5 treatment regimen . Subjects receive study medication 12 week . Study participation 13 week ( 5 clinic visit 1 telephone follow-up ) .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>To eligible study , subject must fulfill follow criterion : 1 . Men woman ≥18 year age . 2 . A diagnosis papulopustular rosacea , ≥10 inflammatory lesion ( papule and/or pustule ) mandibular line baseline . 3 . An Investigator Global Assessment ( IGA ) score ≥2 4 . In good physical mental health . 5 . Signature approve informed consent form study HIPAA authorization ( applicable ) . 6 . Willingness comply protocol . Subjects meet follow criterion exclude study : 1 . A skin examination reveals presence another skin disease and/or condition ( excessive facial hair , excessive scarring , sunburn , disfigurement ) locate face would confound evaluation rosacea condition . 2 . Current past ocular rosacea , conjunctivitis , iritis , keratitis , sufficient severity require topical systemic antibiotic . 3 . Treatment topical antibiotic , topical steroid topical rosacea treatment face within 14 day Baseline throughout study . 4 . Treatment systemic steroid within 30 day Baseline throughout study . 5 . Treatment systemic antibiotic within 30 day Baseline throughout study . 6 . Treatment systemic medication therapy know affect inflammatory response within 30 day prior Baseline throughout study . 7 . Treatment topical retinoids within 30 day systemic retinoids within 180 day Baseline throughout study . 8 . Treatment physical modality could benefit rosacea prohibit within 30 day Baseline throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>rosacea , Papulopustular Rosacea , erythema , dapsone</keyword>
</DOC>